Neuberger Berman Group LLC Purchases 8,135 Shares of Illumina, Inc. $ILMN

Neuberger Berman Group LLC lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 14.2% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 65,322 shares of the life sciences company’s stock after buying an additional 8,135 shares during the quarter. Neuberger Berman Group LLC’s holdings in Illumina were worth $6,204,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ILMN. Integrated Quantitative Investments LLC acquired a new stake in Illumina in the 3rd quarter worth about $1,132,000. Amova Asset Management Americas Inc. grew its position in shares of Illumina by 5.7% during the 3rd quarter. Amova Asset Management Americas Inc. now owns 917,246 shares of the life sciences company’s stock worth $87,028,000 after purchasing an additional 49,265 shares in the last quarter. ARK Investment Management LLC increased its holdings in shares of Illumina by 25.7% during the third quarter. ARK Investment Management LLC now owns 1,467,879 shares of the life sciences company’s stock worth $139,405,000 after purchasing an additional 299,801 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Illumina by 14.4% in the third quarter. Dimensional Fund Advisors LP now owns 557,525 shares of the life sciences company’s stock valued at $52,926,000 after buying an additional 69,997 shares in the last quarter. Finally, Legato Capital Management LLC raised its position in shares of Illumina by 5.9% in the third quarter. Legato Capital Management LLC now owns 25,000 shares of the life sciences company’s stock valued at $2,374,000 after buying an additional 1,400 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on ILMN shares. Barclays increased their price target on Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research report on Monday, December 15th. Robert W. Baird set a $137.00 target price on Illumina in a research report on Friday, February 6th. TD Cowen reissued a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Finally, Piper Sandler dropped their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $129.69.

Insider Buying and Selling

In other Illumina news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider owned 17,887 shares in the company, valued at $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Patricia Leckman sold 2,370 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the transaction, the senior vice president owned 16,321 shares of the company’s stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.60% of the company’s stock.

Illumina Trading Down 2.8%

Shares of ILMN stock opened at $124.62 on Friday. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53. The stock’s fifty day moving average price is $134.37 and its two-hundred day moving average price is $119.24. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The company has a market cap of $19.05 billion, a PE ratio of 22.87, a P/E/G ratio of 2.38 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same quarter in the previous year, the firm earned $0.95 EPS. Illumina’s revenue was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.